— Know what they know.
Not Investment Advice
Also trades as: NUVB-WT (NYSE) · $vol 0M

NUVB NYSE

Nuvation Bio Inc.
1W: +0.7% 1M: -21.4% 3M: -32.6% YTD: -47.4% 1Y: +2.7% 3Y: +272.7% 5Y: -52.3%
$4.55
+0.04 (+0.89%)
After Hours: $4.50 (-0.05, -1.10%)
Weekly Expected Move ±6.9%
$4 $4 $5 $5 $5
NYSE · Healthcare · Biotechnology · Tech Score Strong Sell · Power 34 · $1.6B mcap · 252M float · 2.53% daily turnover · Short 54% of daily vol
Credit Risk of going bust: higher than 73% of companies Debt: 13.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.11 (down 98%), Nuvation Bio Inc. would be worth roughly what it owes.
Total debt $252.1M against a stock market value of $1.58B.
Distance to default 3.20 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $128.2M (short-term plus half of long-term), stock volatility 79.5%; Altman Z'' -0.12. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

📊 Key Metrics

TTM
$170M
Revenue
+1083.6% YoY
$-150M
Net Income
+26.2% YoY
$-121M
Free Cash Flow
+28.3% YoY
97.1%
Gross Margin
-161.1%
Op. Margin
-198.3%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE-47.8%
ROA-21.5%
ROIC70.2%

Valuation

P/E-10.3
P/B6.1
EV/EBITDA-12.4

Leverage

Debt/Equity0.99
Current Ratio8.37
Interest Cov.-6.3x

Quality Scores

Piotroski F4/9
Altman Z0.90
Beneish M1.81

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms